U.S. markets closed

Salarius Pharmaceuticals, Inc. (SLRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.0200-0.0100 (-0.97%)
At close: 4:00PM EDT
1.0301 +0.01 (0.99%)
After hours: 04:29PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.0300
Open1.0300
Bid1.0300 x 36900
Ask1.0500 x 4000
Day's Range1.0200 - 1.0900
52 Week Range0.6320 - 3.5000
Volume1,621,285
Avg. Volume1,647,031
Market Cap45.668M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.3610
Earnings DateJul 14, 2021 - Jul 19, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.10
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • REMINDER: Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event
    GlobeNewswire

    REMINDER: Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event

    Online Event Scheduled for Monday, June 21, 2021, at 2:00 p.m., ET Event to Spotlight Seclidemstat and Feature Experts in the Fields of Epigenetics, Sarcomas, and Hematological Cancers HOUSTON, June 17, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced that it will host a virtual key opinion leader (KOL) and inve

  • Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers
    GlobeNewswire

    Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers

    Clinical trial to target patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML), both cancers that can progress into Acute Myeloid Leukemia (AML)HOUSTON, June 15, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced the initiation of a clinical trial to investigate seclidemstat, a n

  • Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event
    GlobeNewswire

    Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event

    Online Event Scheduled for Monday, June 21, 2021 at 2:00 p.m., ET Event to Spotlight Seclidemstat and Feature Experts in the Fields of Epigenetics, Sarcomas, and Hematological Cancers HOUSTON, June 10, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced that it will host a virtual key opinion leader (KOL) and inves